Search
Now showing items 1-10 of 25
Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma
(2015)
OBJECTIVES
Clinical activity and tolerability of a 14-day infusional ifosfamide schedule in soft-tissue sarcoma
(2013)
Background. Soft-tissue sarcomas (STS) are a heterogeneous group of diseases with lack of effective treatments in most cases. Previous data suggest that continuous infusional ifosfamide regimens might improve cytotoxicity ...
The evolution of systemic therapy in sarcoma
(2013)
Approximately 50% of patients with localized soft tissue sarcomas will develop recurrent disease after complete surgical resection, requiring alternative means of treatment. Conventional chemotherapy comprising of doxorubicin ...
Beyond triple-negative breast cancer: The need to define new subtypes
(2010)
Advances in the systemic treatment of early breast cancer have led to significant improvements in survival for patients with hormone receptor- and/or HER2-positive disease. In recent years, interest has focused on tumors ...
Molecular subtypes and emerging therapeutic opportunities
(Future Medicine Ltd., 2011)
Triple-negative breast cancers comprise a heterogeneous group of tumors with varying prognosis, but the majority are of high histological grade and have a poor prognosis. Although there is considerable overlap between ...
Molecular Classification of Breast Cancer
(2012)
This article reviews the conceptual and practical implications of the intrinsic subtype classification of breast cancers and the limitations of this approach. It presents the most extensively validated gene expression ...
Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis
(2009)
Background: Aggressive fibromatosis (AF) or desmoid tumour is a monoclonal proliferation which is locally invasive but does not metastasize. If local treatment fails to control the disease, systemic treatment with ...
Advanced aggressive fibromatosis: Effective palliation with chemotherapy
(2011)
Background. Aggressive fibromatosis (AF) is a locally invasive proliferative disease. The mainstay of treatment is surgery. Chemotherapy may be considered in inoperable AF following failure of hormonal therapy and/or NSAIDs. ...
Clinical trial design methodologies for advanced sarcoma therapy
(2015)
Sarcomas are rare and heterogeneous mesenchymal tumors affecting connective tissue. For many years, doxorubicin-based chemotherapy has been the main systemic therapy option for patients with metastatic soft tissue sarcoma. ...